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Predict Optimal Angiographic Deployment
Projections for TAVRTranscatheter aortic valve replacement (TAVR) is an
established and accepted therapeutic option for both
inoperable and high-risk surgical patients with severe
aortic stenosis. Precise prosthetic valve positioning inFIGURE 1 Steps in Determining TAVR Coplanar View Using 3D Echo-
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mark (C to E) depicts the head of the transesophageal echocardiography pthe 3-dimensional (3D) aortic annulus is a critical
component of a successful TAVR procedure. Improper
positioning of the prosthetic valve (e.g., too high or
too low in the annulus) may result in device emboli-
zation, coronary obstruction, or paravalvular leak.
Proper valve positioning is best achieved by working
in a 2-dimensional x-ray ﬂuoroscopic view that is
perpendicular to the native valve/annulus (e.g., the
“coplanar view”). Various imaging techniques and
modalities, including standard aortic root x-ray
angiography, multidetector computed tomography,
and 3D angiographic reconstructions of the aortic root
generated by rotational C-arm x-ray angiography,X-Ray Navigation
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848have all been tested and used to determine the opti-
mal angiographic deployment projection angle (1–3).
Thesemodalities, however, remain limited by the need
for iodinated contrast, which carries with it inherent
risks of subsequent renal dysfunction in the elderly
and high-risk TAVR patients. Recently, an integrated
3D Echo-X-Ray navigation system (EchoNavigator,
Philips Healthcare, Eindhoven, the Netherlands) was
employed whereby 3D transesophageal echocardiog-
raphy (TEE) imaging is registered automatically in real
time with live 2-dimensional ﬂuoroscopy images ac-
quired from the x-ray imaging system. Although use of
this integrated navigation system to determine an
optimal x-ray angiographic deployment projection
necessitates the use of TEE during TAVR, it offers the
potential to mitigate some of the contrast agent risk
associated with the alternative imaging modalities.
Figure 1 demonstrates a case example using x-ray/3D
TEE coregistration to accurately predict the optimal
x-ray angiographic deployment projection for TAVR.
Further investigation of the methods described in
this case example should be validated in a larger
series of patients.Michael S. Kim, MD*
John Bracken, PhD
Niels Nijhof, MSc
Ernesto E. Salcedo, MD
Robert A. Quaife, MD
John C. Messenger, MD
John D. Carroll, MD
*University of Colorado Denver
Anschutz Medical Campus
12401 East 17th Avenue, B-132
Aurora, Colorado 80045
E-mail: michael.kim@ucdenver.edu
http://dx.doi.org/10.1016/j.jcmg.2014.01.022
Please note: This work was supported with a research grant to the University of
Colorado Denver from Philips Healthcare. Drs. Kim, Salcedo, Quaife, and Carroll
are consultants for Philips Healthcare. Dr. Bracken is employed full-time by
Philips Research North America as a clinical research associate, stationed at the
University of Colorado Hospital. Mr. Nijhof is employed as a scientist at Philips
Healthcare. Dr. Carroll has received research support and royalties from Philips
Healthcare. Dr. Messenger has reported that he has no relationships relevant to
the contents of this paper to disclose.
RE F E RENCE S
1. Binder RK, Leipsic J, Wood D, et al. Prediction of optimal deployment
projection for transcatheter aortic valve replacement: angiographic
3-dimensional reconstruction of the aortic root versus multidetector
computed tomography. Circ Cardiovasc Interv 2012;5:247–52.
2. Gurvitch R, Wood DA, Leipsic J, et al. Multislice computed tomography
for prediction of optimal angiographic deployment projections during
transcatheter aortic valve implantation. J Am Coll Cardiol Intv 2010;3:
1157–65.
3. Smith LA, Dworakowski R, Bhan A, et al. Real-time three-dimensional
transesophageal echocardiography adds value to transcatheter aortic valve
implantation. J Am Soc Echocardiogr 2013;26:359–69.Effects of Blood T1 on
Extracellular Volume CalculationWe read with much interest the recent publication by
White et al. (1), assessing the accuracy of the contrast
bolus T1 mapping cardiac magnetic resonance
technique for measuring myocardial extracellular
volume fraction (ECV). The study provides the ﬁrst
validation of the bolus technique against collagen
volume fraction from myocardial biopsy. The bolus
technique was also compared with the gold standard
infusion technique in 5 representative conditions.
The 2 techniques provide equivalent results, except
for pathological states with an ECV >0.4, where
the bolus approach consistently and increasingly
overestimates the ECV value.
To date, T1 mapping has been used mainly for
differentiation between healthy and disease states in
clinical settings associated with an increased ECV.
The technique should provide even more clinical
beneﬁt through its ability to differentiate between
different degrees of pathological states associated
with scar or edema in such settings as post-infarction
remodeling, myocarditis, and transplant rejection
follow-up. In this regard, the lower precision of the
bolus technique in the ECV range of myocardial scar
or edema is a matter of concern.
As suggested by the authors, a possible reason for
such ECV overestimation is that renal clearance might
be faster than the exchange rate between the intra-
vascular and interstitial compartments, leading to
lower DR1 in blood compared with DR1 of myocar-
dium with time. This is in line with previous obser-
vations in subjects with normal or modestly increased
ECV, showing small but signiﬁcant changes in ECV
with time using the bolus approach (2,3). This should
cause a slight overestimation in the high ECV range
with the bolus approach, as a limitation of the 2-
compartment model, but independent of noticeable
differences in blood T1 related to the underlying
clinical state.
The data in the present study show some intriguing
differences in blood T1 between groups. Post-contrast
blood T1 is higher for bolus than for infusion in all
subjects except for the healthy and the HCM-remote
groups. This includes therefore all cases of high
ECV (i.e., the Amyloid, HCM LGE Zone, and Infarct
Zone groups in Table 1 in White et al. (1)). As such, the
relative difference in blood T1 between bolus and
infusion (with pre-contrast T1 as the reference) is up
to 4.3 times higher in the high ECV subjects
compared with the healthy or HCM-remote group.
The lower DR1 for blood with the bolus approach in
